Bissonnette R, et al. - In moderate-to-severe psoriasis, authors evaluated the effectiveness and safety of secukinumab through 5 years of treatment. High and sustained levels of skin clearance were demonstrated by secukinumab 300 mg treatment and through 5 years, this treatment improved quality of life in patients with moderate-to-severe psoriasis. In the secukinumab phase 2/3 programme favourable safety established was maintained through 5 years. Findings suggested favourable safety profile of secukinumab, with no cumulative or unexpected safety concerns identified.